INTRODUCTION
The advent of endoscopic ultrasonography (EUS) or echoendoscopy (EE) represented a breaking point in the localization and diagnosis of PNETs (1-4) (insulinomas, gastrinomas, glucagonomas, non-functioning, etc.) as it provided a high yield (sensitivity around 90%, specificity at 98%) (5-10) only second to EUS-FNA (almost 100%) (10) (11) (12) (13) (14) (15) .
New EUS-related technologies such as contrast media and elastography have also improved PNET localization (16) (17) (18) (19) (20) (21) (22) with percentages matching those obtained with EUS-FNA.
A recent paper states that contrast agents (S: 95%) substantially improve conventional EUS findings (21) .
Therefore, diagnostic EUS should be now considered seriously for PNET assessment (10) in addition to elastography, contrast media, both things, or even FNA (22) .
Furthermore, novel imaging techniques other than US (23), CT (24, 25) , and MRI (25, 26) , including PET (FDG & DOPA) and PET-CT, may be used for the localization and staging of PNETs, particularly when no primary tumor has been found (27) (28) (29) (30) (31) (32) (Table I) .
When CT will not find a PNET, EUS does so in 91% of cases (34) . According to several papers EUS is superior to MDCT (Multiple Detector Computerized Tomography) (8, 21, 33, 34) .
PET-CT may be a match for Octreoscan (31) for tumors other than insulinomas, and only PET-CT is superior to Octreoscan when tumors with a high Ki-67 proliferation index are considered (32), with sensitivity approaching 100% when it comes to finding a primary tumor and its related metastases (35) (36) (37) (38) .
Once a tumor is precisely located its staging must ensue in order to decide on its appropriate management (surgical or otherwise) and to define a prognosis according to histopathology (Figs. 1 and 2) (39).
We have moved from the classical TNM system to the WHO histological classification (40):
-Well differentiated: benign, smaller than 2 cm, confined to the pancreas, fewer than 2 mitoses per 10 HPFs, Ki-67 below 2%, and chromogranin A +. No vascular invasion. -Uncertain behavior: confined to the pancreas and one or more of the following: a) larger than 2 cm; b) 2-10 mitoses; c) Ki-67 above 2%; and d) vascular invasion and perineural permeation. CT + Octreoscan + EUS
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